3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
12
Unknown
5
Terminated
3
Recruiting
3
Withdrawn
1
Suspended
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
12
Myelodysplastic Syndromes
4
Neoplasm Metastasis
3
Melanoma
3
Leukemia, Myelomonocytic, Chronic
3
Breast Neoplasms
3
Advanced Solid Tumor
3
Recurrence
2
Ovarian Neoplasms
2
Lymphoma, B-Cell
2
Leukemia, Monocytic, Acute
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Papillomavirus Infections
1
Non-Squamous Non-small Cell Lung Cancer
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Multiple Myeloma
1
Microsatellite Instability
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Basophilic, Acute
1
Leukemia
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
Injections
×
Clear all
NCT05688280
2025-01-08
INJECTABL-1
Immunophotonics, Inc.
Phase 1/2
Active not recruiting
42 enrolled